The firm said the risk-reward for Eli Lilly (NYSE:LLY) is "not attractive," especially given uncertainties surrounding the future growth of its obesity drug franchise. HSBC noted, "We are not ...

Fintel reports that on April 28, 2025, HSBC downgraded their outlook for Eli Lilly and (NYSE:LLY) from Buy to Reduce. Analyst ...

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

Eli Lilly And Co (NYSE:LLY) stock is 1.6% lower to trade at $870.31 at last check, after a rare double downgrade from HSBC to ...

HSBC double downgraded Eli Lilly (LLY) to Reduce from Buy with a price target of $700, down from $1,150. The market has assumed a significant market share for Lilly, but with potential economic ...

HSBC suggests reducing Bajaj Housing Finance ... to become the primary supplier given capacity addition.Orforglipron, Eli Lilly’s potential best-in-class oral GLP-1, is the next addition in ...

HSBC is cautious on pharma stock Eli Lilly (NYSE: LLY), lowering the rating to “reduce” from “buy” amid risk headwinds. IBM (NYSE: IBM) is up 1.1% after earmarking $150 billion to ...

Nvidia (NVDA) is down with the chipmakers in response to President Trump's tariffs, and is also lower after HSBC downgraded Nvidia ... in the coming weeks. - Eli Lilly (LLY) is sinking along ...

Stocktwits - HSBC on Monday double downgraded Eli Lilly and Co. (NYSE:LLY) stock to ‘Reduce’ from ‘Buy’ and also lowered its price target to $700 from $1,150. The new price target represents a 21% ...